Active Recombinant Human Plasminogen

• Cat.No.: PLG-4186H
• Product Overview: Human PLG is produced from Human Fluid is a glycosylated polypeptide chain which migrates as a doublet 50 kDa on SDS-PAGE. The PLG is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: PLG-4186H
• Description: There are several proteolytic fragments or specific domains of proteins that act as inhibitors of angiogenesis. These include fragments of plasminogen such as Angiostatin protein kringles 1-4 and kringles 1-5, Endostatin, Restin, PEX, the N-terminal fragment of prolactin, and the Nterminally truncated platelet factor. Angiostatin is a proteolytic protein fragment of plasminogen that is comprised of the first 4 kringle regions. PLG prevents the growth of endothelial cells, and its systemic administration inhibits the growth of primary carcinomas in mice. Angiostatin Kringles 1-3 segment has a larger inhibitory activity than the Angiostatin kringles 1-4 fragment. The protease-activated angiostatin kringles 1-5 is the most potent plasminogen fragment with over 50 times larger endothelial cell specific inhibitory activity. Angiostatin kringles 1-5 systemic administration inhibits growth of fibrosarcoma and significantly reduces neovascularization. Angiostatin is an angiogenesis inhibitor in mouse serum and urine. Angiostatin is a 38 kDa protein fragment of the plasminogen composed of the 1st 4 kringle domains of plasminogen. PLG is also named plasminogen kringles 1-4 and PK1-4. Angiostatin protein is manufactured by the protelytic cleavage of plasminogen by a serine protease from several prostate carcinoma cell lines. The manufacturing of angiostatin by pancreatic cancer cells can be inhibited by TGF-beta 1 along with plasminogen activator inhibitor type-1 (PAI1).
• Source: Human
• Host: Human Fluid
• Form: Lyophilized from a (1mg/ml) solution in containing 20mM Hepes buffer pH-8.2 & 20mM NaCl.
• Purity: Greater than 98.0% as determined by SDS-PAGE.
• Bio-activity: Human PLG significantly inhibits basic-FGF induced endothelial cell proliferation and migration at concentration ranging from 300nM-1.0 uM.
• Physical Appearance: Sterile Filtered lyophilized powder.
• Solubility: It is recommended to reconstitute the lyophilized PLG in sterile 18Mμ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
• Storage: Lyophilized PLG although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution PLG should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.
• Tag: Non

Gene Information

• Gene Name: PLG plasminogen [ Homo sapiens ]
• Official Symbol: PLG
• Synonyms: PLG; plasminogen; DKFZp779M0222; plasmin; OTTHUMP00000017544; OTTHUMP00000017545; OTTHUMP00000197002
• Gene ID: 5340
• mRNA Refseq: NM_000301
• Protein Refseq: NP_000292
• MIM: 173350
• UniProt ID: P00747
• Chromosome Location: 6q26
• Pathway: Blood Clotting Cascade; Complement and Coagulation Cascades; Diabetes pathways; Dissolution of Fibrin Clot; Formation of Platelet plug; Hemostasis; Influenza A; Platelet Activation; Platelet degranulation; Selenium Pathway; Signaling by PDGF; Staphylococcus aureus infection; Syndecan-4-mediated signaling events; amb2 Integrin signaling; p75(NTR)-mediated signaling
• Function: apolipoprotein binding; cell surface binding; peptidase activity; protein binding; serine-type endopeptidase activity

Reviews

06/12/2022

The tightly sealed packaging of this protein reagent ensures optimal preservation of its activity.

11/18/2021

I highly recommend this reagent for its simplified experimental workflow, saving time and experimental costs.

08/10/2019

Catering to diverse experimental needs, its outstanding performance facilitates diversity in scientific research.

Q&As

What is the clinical significance of PLG as a diagnostic or prognostic biomarker?

PLG has been investigated as a potential diagnostic and prognostic biomarker for various diseases. For instance, altered PLG levels have been observed in cancer patients, serving as a potential marker for tumor progression and prognosis. Additionally, PLG has been implicated in cardiovascular diseases, where its levels can reflect the severity of certain conditions, such as thrombosis. Moreover, PLG may have utility as a biomarker in inflammatory disorders and neurological diseases. Further research is needed to validate the clinical utility of PLG as a biomarker and develop specific assays for its detection.

What are the pathological implications of PLG dysregulation?

Dysregulation of PLG has been associated with several pathological conditions. Decreased PLG levels or impaired activation can lead to impaired fibrinolysis, resulting in the formation of excessive blood clots. On the other hand, increased PLG activation or excessive Plasmin activity can promote tissue degradation, contributing to diseases such as chronic inflammation, cancer metastasis, and tissue damage. Moreover, PLG has been implicated in the pathogenesis of neurodegenerative disorders and cardiovascular diseases. Understanding the mechanisms underlying PLG dysregulation is crucial for designing therapeutic strategies to counteract its pathological implications.

What therapeutic strategies target PLG for the treatment of diseases?

PLG-targeted therapeutic strategies have shown promise in various diseases. For example, agents that enhance PLG activation, such as tPA and uPA, have been employed to promote fibrinolysis and dissolve blood clots in conditions such as heart attacks and ischemic strokes. Conversely, inhibitors of PLG activation, such as PAIs, can be used to prevent excessive fibrinolysis and subsequent bleeding complications. Additionally, targeting PLG receptors or manipulating PLG interactions with other molecules may offer potential therapeutic avenues. However, further research is required to optimize these strategies and assess their efficacy and safety in clinical settings.

What is the full name and structure of the PLG protein?

The PLG protein, also known as Plasminogen, is a single-chain glycoprotein composed of 790 amino acids. It consists of several domains, including a signal peptide, five kringle domains (K1-K5), and a serine protease domain. The signal peptide mediates protein secretion, while the kringle domains have numerous functions, such as binding to receptors and ligands. The serine protease domain is responsible for the conversion of Plasminogen to active Plasmin, a crucial enzyme in fibrinolysis and extracellular matrix remodeling processes.

What are the physiological functions of PLG in the human body?

PLG plays a vital role in several physiological processes. Its primary function is as a precursor to Plasmin, which is involved in the degradation of blood clots (fibrinolysis). Plasmin also participates in tissue remodeling, wound healing, and cell migration. Additionally, PLG has been implicated in immune responses, angiogenesis, and cell adhesion. Its ability to interact with various receptors and bind to components of the extracellular matrix highlights its diverse and important functions in maintaining normal physiological homeostasis.

What is the biological function of PLG?

PLG, also known as plasminogen, plays a crucial role in the fibrinolytic system. Its main biological function is to be converted into plasmin, an enzyme that breaks down fibrin clots. Plasminogen is activated by tissue plasminogen activator (tPA), which cleaves it into active plasmin. Plasmin then degrades fibrin clots, preventing the formation of thrombi and promoting the dissolution of existing blood clots. Additionally, PLG is involved in various physiological processes, such as wound healing, tissue remodeling, cell migration, and inflammation.

How is the activation of PLG regulated?

The activation of PLG is tightly regulated to prevent undesired fibrinolysis. Activation can occur through two main pathways: the tissue-type Plasminogen Activator (tPA)-dependent pathway and the urokinase-type Plasminogen Activator (uPA)-dependent pathway. In the tPA-dependent pathway, tPA binds to a specific receptor on the cell surface and catalyzes the conversion of PLG to Plasmin. The uPA-dependent pathway involves uPA binding to a receptor, followed by the activation of PLG. Additionally, various regulatory proteins, such as Plasminogen Activator Inhibitors (PAIs), control PLG activation by inhibiting the activity of tPA and uPA.